MannKind
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.About MNKD
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.
MNKD Key Statistics
Stock Snapshot
MannKind(MNKD) stock is priced at $5.77, giving the company a market capitalization of 1.78B. It carries a P/E multiple of 61.40.
During the trading session on 2025-12-29, MannKind(MNKD) shares reached a daily high of $5.92 and a low of $5.76. At a current price of $5.77, the stock is +0.2% higher than the low and still -2.5% under the high.
Trading volume for MannKind(MNKD) stock has reached 2.41M, versus its average volume of 3.86M.
The stock's 52-week range extends from a low of $3.38 to a high of $6.88.
The stock's 52-week range extends from a low of $3.38 to a high of $6.88.
MNKD News
MannKind Corporation recently reported that the FDA approved a supplemental New Drug Application expanding FUROSCIX on-body Infusor use to pediatric patients we...
Key Points CEO Michael Castagna sold 65,804 shares on Dec. 17, 2025, for a total value of approximately ~$395,482 at a weighted average price around $6.01 per...
MannKind (MNKD) announced two business updates-approval of the FUROSCIX On-body Infusor for pediatric patients and issuance of additional intellectual property...